Helmedix Overview

  • Founded
  • 2012
  • Status
  • Private
  • Latest Deal Type
  • Seed
  • Latest Deal Amount
  • $1.29M
Latest Deal Amount
  • Investors
  • 1

Helmedix General Information


Developer of therapeutic peptide drugs designed to help for treating autoimmune and inflammatory diseases. The company's drugs are based on a number of immune-modulating peptides derived from helminth parasites effective in suppressing the inflammatory response of the host and shows therapeutic potential in a mouse model of type 1 diabetes, enabling medical professionals to treat rheumatoid arthritis, colitis, psoriasis and multiple sclerosis.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Primary Office
  • Sydney, New South Wales
  • Australia
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Helmedix Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Seed Round 15-Feb-2013 $1.29M 00.000 Completed Startup
To view Helmedix’s complete valuation and funding history, request access »

Helmedix Executive Team (5)

Name Title Board Seat Contact Info
John Dalton Ph.D Co-Founder & Director
Mark Robinson Ph.D Co-Founder
Sheila Donnelly Ph.D Co-Founder
Henry Thompson Ph.D Director
You’re viewing 4 of 5 executive team members. Get the full list »

Helmedix Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Brandon Capital Partners Venture Capital Minority 000 0000 000000 0
To view Helmedix’s complete investors history, request access »